NEUROCRINE BIOSCIENCES INC (NBIX) Total liabilities 2016–2025
NEUROCRINE BIOSCIENCES INC (NBIX) total liabilities at each fiscal year-end, per SEC filings.
$1.4BFY2025 · since FY2016: $50.2M → $1.4B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.4B | +22.1% |
| FY2024 | $1.1B | +10.8% |
| FY2023 | $1.0B | +54.2% |
| FY2022 | $660.9M | -5.4% |
| FY2021 | $698.5M | +14.8% |
| FY2020 | $608.5M | -9.1% |
| FY2019 | $669.1M | +30.6% |
| FY2018 | $512.4M | +15.0% |
| FY2017 | $445.5M | +787.2% |
| FY2016 | $50.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NBIX financial trends
NBIX RevenueNBIX Net incomeNBIX Net marginNBIX Gross profitNBIX Gross marginNBIX Operating incomeNBIX Operating marginNBIX Operating cash flowNBIX Free cash flowNBIX Capital expendituresNBIX Return on equityNBIX Stock buybacksNBIX Dividends paidNBIX Total assetsNBIX Shareholders’ equityNBIX overview →